Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab versus chemotherapy as second-line therapy in small cell lung cancer
2016-003795-49Phase 2Completed
- Sponsor
- IFCT
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in small cell lung cancer (SCLC) (2 arms), sponsored by IFCT. Primary endpoint: Response rate in the experimental arm. Started Jan 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2016-003795-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003795-49.